Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

CAR T cells generated in vivo

17.09.2018

In August 2018, two CAR T cell therapeutics obtained marketing authorization from the European Commission. They provide efficacious treatment options for patients suffering from certain forms of leukemia and who have not responded to other treatment options. However, manufacturing CAR T cells that are composed of genetically engineered patient immune cells is laborious: the cells are taken from the patient, genetically modified with the CAR, multiplied and then reinfused. Researchers of the Paul-Ehrlich-Institut (PEI) succeeded in animal experiments to engineer CAR-T cells directly in the living organism. EMBO Mol Med reports on the research results in its online issue of 17 September 2018.

Cancer cells often escape the immune system unrecognized. A new form of cancer therapy aims at tackling this by retargeting immune cells against the cancer cells. CAR T cells belong to this cancer immunotherapies.


Schematic representation of CAR T cell generation. On the left, ex vivo CAR T cell generation, on the right, vector particle, which selectively introduces genetic information for the CAR into T cells

Source: EMBO Mol Med

This involves removing certain immune cells (T cells) from the patient, equipping them outside the body with a chimeric (synthetic) antigen receptor (CAR), amplification and retransplantation into the patient. The antigen receptor recognizes distinct surface structures, in case of the authorized products, the CD19 antigen on cancer cells. Being equipped with the chimeric antigen receptor, the immune cells can recognize and kill cancer cells.

This therapy resulted in some patients, who had not profited from standard care, in the complete elimination of cancer cells and their absence over many years. Manufacturing such products is however laborious: The cells have to be harvested from the patient, must be genetically modified outside the body and then reinfused. Moreover, the distinct steps of this process can inadvertently alter the immune cells and their activities.

Researchers led by Prof Christian Buchholz at the Paul-Ehrlich-Institut, head of the research group „Molecular Biotechnology and Gene Therapy“ of the Paul-Ehrlich-Institut, succeeded within a research project funded by the German Cancer Aid together with collaboration partners, in achieving this genetic modification of human T cells directly in vivo, i.e in the living organism.

The key factor for this success were specifically modified lentiviral vector particles transferring the CAR gene selectively into those T cell subtypes being responsible for cancer attack. For their proof-of-principle demonstration, the researchers used mice that had been equipped with human blood cells.

A single intravenous injection of the vector particles was sufficient to generate sufficient numbers of CAR T cells that became detectable in blood and lymphatic organs. These in vivo generated CAR T cells proliferated upon antigen contact and eliminated CD19-positive cells. As observed in clinical applications, some animals experienced cytokine release syndrome and neurotoxicity.

This is the first proof-of-concept demonstration that human cytotoxic T cells can be reprogrammed into CAR T cells and kill target cells. The implications of these results are plentifold: The animal model will facilitate research into the side-effects caused by CAR T cell therapy.

The technology of genetically modifying T cells in vivo will be potentially applied in other fields of immunotherapy. Finally, the results form the basis to transform the CAR T cell therapy from an individualized into an universally applicable therapy. This could impact the economic feasibility of this therapy enormously, but, requires, however, a series of preclinical studies first.


The Paul-Ehrlich-Institut, the Federal Institute for Vaccines and Biomedicines, in Langen near Frankfurt/Main is a senior federal authority reporting to the Federal Ministry of Health (Bundesministerium für Gesundheit, BMG). It is responsible for the research, assessment, and marketing authorisation of biomedicines for human use and immunological veterinary medicinal products. Its remit also includes the authorisation of clinical trials and pharmacovigilance, i.e. recording and evaluation of potential adverse effects.

Other duties of the institute include official batch control, scientific advice and inspections. In-house experimental research in the field of biomedicines and life science form an indispensable basis for the manifold tasks performed at the institute.

The Paul-Ehrlich-Institut, with its roughly 800 members of staff, also has advisory functions nationally (federal government, federal states (Länder)), and internationally (World Health Organisation, European Medicines Agency, European Commission, Council of Europe etc.).

Originalpublikation:

Pfeiffer A, Thalheimer FB, Hartmann S, Frank AM, Bender RR, Danisch S, Costa C, Wels WS, Modlich U, Stripecke R, Verhoeyen E, Buchholz CJ (2018): In vivo generation of human CD19-CAR T cells results in B cell depletion and signs of cytokine release syndrome.
EMBO Mol Med Sep 17 [Epub ahead of print].
DOI: 10.15252/emmm.201809158

Weitere Informationen:

http://embomolmed.embopress.org/cgi/doi/10.15252/emmm.201809158 - Fulltext of the Publication
https://www.pei.de/EN/information/journalists-press/press-releases/2018/16-car-t... - this press release on the PEI-Website

Dr. Susanne Stöcker | idw - Informationsdienst Wissenschaft

More articles from Life Sciences:

nachricht First SARS-CoV-2 genomes in Austria openly available
03.04.2020 | CeMM Forschungszentrum für Molekulare Medizin der Österreichischen Akademie der Wissenschaften

nachricht Do urban fish exhibit impaired sleep? Light pollution suppresses melatonin production in European perch
03.04.2020 | Leibniz-Institut für Gewässerökologie und Binnenfischerei (IGB)

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Harnessing the rain for hydrovoltaics

Drops of water falling on or sliding over surfaces may leave behind traces of electrical charge, causing the drops to charge themselves. Scientists at the Max Planck Institute for Polymer Research (MPI-P) in Mainz have now begun a detailed investigation into this phenomenon that accompanies us in every-day life. They developed a method to quantify the charge generation and additionally created a theoretical model to aid understanding. According to the scientists, the observed effect could be a source of generated power and an important building block for understanding frictional electricity.

Water drops sliding over non-conducting surfaces can be found everywhere in our lives: From the dripping of a coffee machine, to a rinse in the shower, to an...

Im Focus: A sensational discovery: Traces of rainforests in West Antarctica

90 million-year-old forest soil provides unexpected evidence for exceptionally warm climate near the South Pole in the Cretaceous

An international team of researchers led by geoscientists from the Alfred Wegener Institute, Helmholtz Centre for Polar and Marine Research (AWI) have now...

Im Focus: Blocking the Iron Transport Could Stop Tuberculosis

The bacteria that cause tuberculosis need iron to survive. Researchers at the University of Zurich have now solved the first detailed structure of the transport protein responsible for the iron supply. When the iron transport into the bacteria is inhibited, the pathogen can no longer grow. This opens novel ways to develop targeted tuberculosis drugs.

One of the most devastating pathogens that lives inside human cells is Mycobacterium tuberculosis, the bacillus that causes tuberculosis. According to the...

Im Focus: Physicist from Hannover Develops New Photon Source for Tap-proof Communication

An international team with the participation of Prof. Dr. Michael Kues from the Cluster of Excellence PhoenixD at Leibniz University Hannover has developed a new method for generating quantum-entangled photons in a spectral range of light that was previously inaccessible. The discovery can make the encryption of satellite-based communications much more secure in the future.

A 15-member research team from the UK, Germany and Japan has developed a new method for generating and detecting quantum-entangled photons at a wavelength of...

Im Focus: Junior scientists at the University of Rostock invent a funnel for light

Together with their colleagues from the University of Würzburg, physicists from the group of Professor Alexander Szameit at the University of Rostock have devised a “funnel” for photons. Their discovery was recently published in the renowned journal Science and holds great promise for novel ultra-sensitive detectors as well as innovative applications in telecommunications and information processing.

The quantum-optical properties of light and its interaction with matter has fascinated the Rostock professor Alexander Szameit since College.

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

13th AKL – International Laser Technology Congress: May 4–6, 2022 in Aachen – Laser Technology Live already this year!

02.04.2020 | Event News

“4th Hybrid Materials and Structures 2020” takes place over the internet

26.03.2020 | Event News

Most significant international Learning Analytics conference will take place – fully online

23.03.2020 | Event News

 
Latest News

Capturing 3D microstructures in real time

03.04.2020 | Materials Sciences

First SARS-CoV-2 genomes in Austria openly available

03.04.2020 | Life Sciences

Do urban fish exhibit impaired sleep? Light pollution suppresses melatonin production in European perch

03.04.2020 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>